MAPK3 and cancer: We recently discovered that the cancer-specific activation of FCH/F-BAR and Double SH3 Domain-Containing Protein (FCHSD2) downstream of extracellular signal-regulated kinases 1 and 2 (ERK1/2) contributes to adaptive CME in NSCLC cells [15], in this case by suppressing epidermal growth factor receptor (EGFR) signaling.